Document Type
Article
Disciplines
3. MEDICAL AND HEALTH SCIENCES
Abstract
The JADE family comprises three members encoded by individual genes and roles for these proteins have been identified in chromatin remodeling, cell cycle progression, cell regeneration and the DNA damage response. JADE family members, and in particular JADE2 have not been studied in any great detail in cancer. Using a series of standard biological and bioinformatics approaches we investigated JADE2 expression in surgically resected non-small cell lung cancer (NSCLC) for both mRNA and protein to examine for correlations between JADE2 expression and overall survival. Additional correlations were identified using bioinformatic analyses on multiple online datasets. Our analysis demonstrates that JADE2 expression is significantly altered in NSCLC. High expression of JADE2 is associated with a better 5-year overall survival. Links between JADE2 mRNA expression and a number of mutated genes were identified, and associations between JADE2 expression and tumor mutational burden and immune cell infiltration were explored. Potential new drugs that can target JADE2 were identified. The results of this biomarker-driven study suggest that JADE2 may have potential clinical utility in the diagnosis, prognosis and stratification of patients into various therapeutically targetable options.
DOI
https://doi.org/10.3390/biomedicines11092576.
Recommended Citation
Murphy, Ciara; Pons, Gloria Gornes; Keogh, Anna; Ryan, Lisa; McCarra, Lorraine; Jose, Chris Maria; Kesar, Shagun; Nicholson, Siobhan; Fitzmaurice, Gerard J.; Ryan, Ronan; Young, Vincent; Cuffe, Sinead; Finn, Stephen P.; and Gray, Steven, "An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC)" (2023). Articles. 364.
https://arrow.tudublin.ie/scschbioart/364
Funder
This research was part-funded by a Pathological Society Trainee’s Small Grant to A.K., S.P.F. and S.G.G.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Share Alike 4.0 International License.
Publication Details
https://pubmed.ncbi.nlm.nih.gov/37761019/#:~:text=Our%20analysis%20demonstrates%20that%20JADE2,better%205%2Dyear%20overall%20survival.
Murphy C, Gornés Pons G, Keogh A, Ryan L, McCarra L, Jose CM, Kesar S, Nicholson S, Fitzmaurice GJ, Ryan R, Young V, Cuffe S, Finn SP, Gray SG. An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC). Biomedicines. 2023 Sep 19;11(9):2576.
doi: 10.3390/biomedicines11092576.